Tarsus-acquired IRX-101 cuts injection pain and corneal damage versus iodine antiseptic
The completed 154-patient RELIEF trial hit statistical significance on pain and corneal staining, but the trial's own registered safety endpoint result was not disclosed in the acquisition announcement.
Executive Summary
- A completed randomized trial of an ocular antiseptic showed statistically significant reductions in post-procedural pain and corneal surface damage compared with the decades-old standard antiseptic, in a disclosure tied to an acquisition rather than a standalone trial readout.
- The endpoints the announcement highlights are not the endpoint the trial was registered to test, and no result was disclosed for the endpoint that was actually registered as primary.
- The antiseptic used before intravitreal eye injections has not changed in more than four decades, despite causing recurring pain and corneal damage in a large volume of a routine procedure, leaving room for a better-tolerated alternative if the signal holds up.
- The acquiring company plans to move the program into a larger confirmatory trial rather than seek approval on this dataset, pushing the next test of the signal out by roughly two years.
The disclosure
Tarsus Pharmaceuticals announced on July 8, 2026 that it acquired iRenix Medical, Inc. and disclosed completed results from RELIEF, a Phase 2b/3 trial of IRX-101, a stable aqueous chlorine dioxide solution used before intravitreal eye injections. In the 154-patient randomized trial, IRX-101 produced a roughly 50% relative reduction in post-procedural pain scores (p=0.0003) and a roughly 25% relative reduction in corneal fluorescein staining, a measure of corneal surface damage (p=0.0003), compared with povidone-iodine, the antiseptic currently used before these injections. Tarsus Chief Medical spokesperson David Brown, Chief Medical Officer at Retina Consultants of America, said patients "regularly tell us the burning and irritation after treatment are among the most difficult parts of repeated injections". TarsusTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage ...Jul 8, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial was designed to test
RELIEF, registered as NCT05747430, listed its primary endpoint as safety of the new drug, with three secondary endpoints covering patient-reported post-injection pain and corneal fluorescein staining scores. The trial was a randomized, active-comparator design against povidone-iodine, run at seven U.S. sites, enrolling adults already receiving intravitreal anti-VEGF injections. No safety result accompanied the pain and corneal-staining figures in the disclosure, even though safety was the endpoint the trial was registered to measure. NCT05747430+1SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)NCT05747430Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage ...Jul 8, 2026
Enrollment and timeline
The trial's anticipated enrollment moved from 500 to 240 to 75 patients between February and June 2023, before the registry recorded 155 actual patients enrolled at completion in April 2026, alongside a status change from Recruiting to Unknown status in mid-2025 and then to Completed. That final enrollment figure represents an increase from the last anticipated target, and the operational risk model's own baseline for this kind of shift describes it as within the routine band for a design like this one. The trial ran from a February 2023 start to a March 2025 primary completion date, and results were disclosed publicly more than a year later, folded into an acquisition announcement rather than a standalone readout. NCT05747430+1SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)NCT05747430Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage ...Jul 8, 2026
The competitive frame
No competitor trial in the ClinicalTrials.gov record shares IRX-101's target, mechanism, or modality in this indication, and the market for pre-injection ocular antiseptics has not seen a new FDA-approved entrant in more than four decades, per the disclosure. More than 11 million intravitreal injections are performed annually in the United States, the large majority using povidone-iodine, which the disclosure describes as causing ocular surface toxicity and pain that can persist for days. With no validated alternative mechanism established in this setting, a result that holds on the registered safety endpoint, and not just the two measures Tarsus highlighted, would be the finding that moves this program past a well-tolerated observation toward a differentiated antiseptic. TarsusTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage ...Jul 8, 2026
What comes next
Tarsus said the Phase 3 program is FDA-aligned and plans to begin enrolling in the first half of 2027, with results anticipated in 2028. That timeline means the registered safety question, and any confirmation of the pain and corneal-staining effect at a larger scale, will not be tested again for roughly two years. TarsusTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage ...Jul 8, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.